Emily Ricketts

Vice President, Innovation & Integration
WCG
 

Em is Vice President, Operational Strategy & Planning for WCG’s Patient Advocacy & Diversity team. She designs DE&I programs for our clients at the portfolio, asset or study level. These programs incorporate foundational principles of DE&I, robust strategic frameworks, pragmatic operational plans, and customized guidance for measuring outcomes.

She spent the first decade of her career as a consultant in a large European management consulting firm, specializing in strategic marketing for technology clients including IBM, AT&T and the Bell Operating companies. She entered clinical development in 2004 at Wyeth. There, she built a technology-enabled centralized operations department covering country and site selection, feasibility, recruitment modelling and enrollment reporting. After the acquisition of Wyeth by Pfizer, Em was hired in Pfizer’s Portfolio Metrics team. She served as a principal analyst for the Clinical Trials Excellence Initiative run by Briggs Morrison, a Six Sigma project in which the end-to-end clinical development process framework was analyzed for critical-to-quality elements. Em worked closely with the respective process owners to build operational metrics for monitoring and controlling quality.

Em then worked as an Executive Director at Covance in Operational Strategy & Planning, leading a large multi-functional team that covered Country and Site Selection and Feasibility. While at Covance, she implemented a successful initiative to build a global network of over 75 site partnerships to serve the needs of multiple therapeutic areas and phases of research.

Em holds a B.A. from Rutgers University in Romance Languages, and a M.S. in Computer Science from Penn State.